Cellontech, a medical device company specializing in biocollagen, announced on the 16th that its sales for the first quarter of this year reached 4.9 billion KRW, a 61.9% increase compared to the same period last year. Operating profit turned positive, reaching 1.4 billion KRW. This means that in just one quarter, the company achieved 44% of last year's total operating profit of 3.2 billion KRW. Net profit was recorded at 900 million KRW, a 178.6% increase year-on-year.
Since being incorporated as a subsidiary of SC Engineering in 2021, Cellontech's sales have steadily grown, rising from 7.2 billion KRW in 2021 to 18.2 billion KRW last year.
This growth is the result of strong sales of the intra-articular injection Cartizol. Through joint marketing with LG Chem, Kolon Pharmaceuticals, and Dongkook Pharmaceutical, the company has significantly accelerated its expansion in the domestic market. Additionally, by establishing a year-round, uninterrupted production system at its Seongsu-dong facility in Seoul, Cellontech has secured both supply stability and production efficiency.
A Cellontech representative stated, "Building on the growth of domestic sales, we are continuing to accelerate our efforts to enter the global market. Based on partnerships with leading companies such as China’s Sihuan Pharmaceutical and Just Medical Devices, we have secured a minimum order quantity (MOQ) worth approximately 125 billion KRW."
The representative added, "Once the new biocollagen medical device plant, which is being developed with the goal of beginning operations next year, is completed, our ability to respond to global demand will be greatly enhanced."
Furthermore, the representative explained, "The clinical trials in China, currently being led by Sihuan Pharmaceutical and Just Medical Devices, are progressing rapidly. With the launch of the new plant, we aim to reach a turning point where overseas sales surpass domestic sales."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
